How cryolipolysis with KRYOKONTUR® works
The principle of cryolipolysis is based on a highly controlled cooling technology that damages isolated fat cells by precisely targeted tissue cooling limited in location and time in such a way that they are broken down by the body and thereby permanently removed.

This is achieved with an “applicator” that is laid over the “problem zones” during treatment. This applicator covers, for instance, the entire stomach and works like a suction cup with slight partial vacuum that sucks on the skin together with the fatty tissue beneath it. Then this area of skin with the fatty tissue beneath it is cooled down very precisely for about one hour to exactly the temperature that is needed to damage the fat cells and thereby to permanently remove them.

The same applies to the treatment of the inside and outside (“saddlebags”) of the thigh.

To date no damage has been detected to the skin, nerves, muscles or other tissues as a result of this treatment process.

Only the cooled and hence damaged fat cells are recognised as defective by phagocytes (marcophages) over the next few days and weeks.
They slowly break down the affected cells over the next 2-4 months. The fat released during this period is gradually and naturally transported away via the blood and lymphatic systems and processed in the liver. In clinical trials, no increase in blood fats was detected after cryolipolysis.

Most patients do not find the process uncomfortable or painful. Initially they feel only a light sensation of cooling and pressure which in any event fades in about 10 minutes. After that the treatment is very comfortable and no painkillers are needed. And patients can drink, read or even sleep while it is going on.

Patients can return to their normal activities including work and sport immediately after the treatment.

The following patients should not be given this treatment:

  • Patients with cryoglobulinaemia or paroxysmal cold haemoglobinuria
  • Patients with cold urticaria and with peripheral circulation problems e.g. Raynaud’s syndrome should be critically assessed.
  • Pregnant and breastfeeding patients should on no account be given this treatment.
  • Patients with large scars, eczema or psoriasis in the area to be treated and also patients with paraesthesia or a history of bleeding. In addition, any noticeable autoimmune diseases or underlying haematological diseases should be investigated.

The following expected side effects may be noted:

After the treatment, the treated area feels frozen. This disappears after a few minutes.

Mild reddening may persist for 1 to 3 hours. There might be slight pain immediately afterwards. Very rarely (less than 1%), haematomas (blue spots) will appear in the treated area, which will disappear only a few weeks later. Occasionally, even several weeks after the treatment, paraesthesia (prickling sensation, slight pain, similar to aching muscles) might occur in the treated area. This occurs more often in men than women. If any of these changes persist for a longer time, contact the doctor who treated you.